Breaking news was received a short while ago, in which it stated that the Ministry of Health and Community Protection in the UAE had approved the use of the new vaccine based on recombinant protein, from the company “Sinopharma CNPG”.
In this context, and within the framework of the Ministry’s comprehensive and integrated efforts, in cooperation with health authorities, to enhance the protection of community members from the Covid 19 pandemic in the country, and after conducting a study on some participants who were previously vaccinated with two doses of the inactive “Sinopharma CNPG” vaccine against Covid-19, Where the seroconversion rate was recorded as 100% of neutralizing antibodies, this was accompanied by high safety rates and the absence of serious side effects for all participants. The UAE Ministry of Health approved the emergency use of the “new recombinant protein-based vaccine” from the company “Sinopharma CNPG” “.
The ministry also reported that the vaccine showed an improved immune capacity against the mutants emerging from the SARS-CoV-2 virus, with a high safety rate that allows rapid production and easy storage and distribution.
The Ministry has approved the manufacture and distribution of the new vaccine by Hayat Biotech, a joint venture between Sinopharma CNPG and G42, where the vaccine will be available to the public as a booster dose as of the beginning of 2022 as part of the measures taken to contain Virus spread.
It is worth noting that the UAE is the largest country in the world with coverage of the Covid-19 vaccine, as more than 22 million doses were provided until December 23, 2021, according to what was published by Emirates News.